ProMetic Life Sciences Inc. – Product Pipeline Review

Global Markets Direct’s, ‘ProMetic Life Sciences Inc. – Product Pipeline Review – 2016’, provides an overview of the ProMetic Life Sciences Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ProMetic Life Sciences Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of ProMetic Life Sciences Inc.

The report provides overview of ProMetic Life Sciences Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses ProMetic Life Sciences Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features ProMetic Life Sciences Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate ProMetic Life Sciences Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for ProMetic Life Sciences Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding ProMetic Life Sciences Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

ProMetic Life Sciences Inc. Snapshot 5

ProMetic Life Sciences Inc. Overview 5

Key Information 5

Key Facts 5

ProMetic Life Sciences Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

ProMetic Life Sciences Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

ProMetic Life Sciences Inc. - Pipeline Products Glance 13

ProMetic Life Sciences Inc. - Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

ProMetic Life Sciences Inc. - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

ProMetic Life Sciences Inc. - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

ProMetic Life Sciences Inc. - Drug Profiles 17

immune globulin (human) 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

plasminogen (human) 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

PBI-4050 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

alpha-1 proteinase inhibitor (human) 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

C1 esterase inhibitor (human) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

PBI-4419 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

PBI-4425 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

PBI-4547 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

plasminogen (recombinant) 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ProMetic Life Sciences Inc. - Pipeline Analysis 28

ProMetic Life Sciences Inc. - Pipeline Products by Target 28

ProMetic Life Sciences Inc. - Pipeline Products by Route of Administration 29

ProMetic Life Sciences Inc. - Pipeline Products by Molecule Type 30

ProMetic Life Sciences Inc. - Pipeline Products by Mechanism of Action 31

ProMetic Life Sciences Inc. - Recent Pipeline Updates 32

ProMetic Life Sciences Inc. - Dormant Projects 38

ProMetic Life Sciences Inc. - Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

ProMetic Life Sciences Inc., Key Information 5

ProMetic Life Sciences Inc., Key Facts 5

ProMetic Life Sciences Inc. – Pipeline by Indication, 2016 7

ProMetic Life Sciences Inc. – Pipeline by Stage of Development, 2016 9

ProMetic Life Sciences Inc. – Monotherapy Products in Pipeline, 2016 10

ProMetic Life Sciences Inc. – Partnered Products in Pipeline, 2016 11

ProMetic Life Sciences Inc. – Partnered Products/ Combination Treatment Modalities, 2016 12

ProMetic Life Sciences Inc. – Phase III, 2016 13

ProMetic Life Sciences Inc. – Phase II, 2016 14

ProMetic Life Sciences Inc. – Phase I, 2016 15

ProMetic Life Sciences Inc. – Preclinical, 2016 16

ProMetic Life Sciences Inc. – Pipeline by Target, 2016 28

ProMetic Life Sciences Inc. – Pipeline by Route of Administration, 2016 29

ProMetic Life Sciences Inc. – Pipeline by Molecule Type, 2016 30

ProMetic Life Sciences Inc. – Pipeline Products by Mechanism of Action, 2016 31

ProMetic Life Sciences Inc. – Recent Pipeline Updates, 2016 32

ProMetic Life Sciences Inc. – Dormant Developmental Projects,2016 38

ProMetic Life Sciences Inc., Other Locations 39

ProMetic Life Sciences Inc., Subsidiaries 40

List of Figures

List of Figures

ProMetic Life Sciences Inc. – Pipeline by Top 10 Indication, 2016 7

ProMetic Life Sciences Inc. – Pipeline by Stage of Development, 2016 9

ProMetic Life Sciences Inc. – Monotherapy Products in Pipeline, 2016 10

ProMetic Life Sciences Inc. – Pipeline by Target, 2016 28

ProMetic Life Sciences Inc. – Pipeline by Route of Administration, 2016 29

ProMetic Life Sciences Inc. – Pipeline by Molecule Type, 2016 30

ProMetic Life Sciences Inc. – Pipeline Products by Mechanism of Action, 2016 31

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports